{"id":"W2741722460","doi":"10.1158/1538-7445.am2017-ct070","title":"Abstract CT070: A open-label phase 3b/4 safety trial of flat-dose nivolumab in combination with ipilimumab in patients with advanced non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Internal medicine; Oncology; Lung cancer; Adverse effect; Combination therapy; Discontinuation; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002087888,0.00222259,0.001757292,0.0006124452,0.0007183466,0.001496511,0.00156836,0.002142231,0.009051218],"category_scores_gemma":[0.001326886,0.0006788294,0.00178177,0.0005622893,0.001495639,0.001310274,0.0004944783,0.005110906,0.002461179],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002071977,"about_ca_system_score_gemma":0.003114635,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002238047,"about_ca_topic_score_gemma":0.005812967,"domain_scores_codex":[0.9993153,0.0003692679,0.00003344695,0.0001106166,0.00006509119,0.0001063778],"domain_scores_gemma":[0.9988493,0.0001349714,0.0002024091,0.0000806411,0.000121005,0.0006116417],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.863027,0.05008412,0.003806588,0.000828893,0.001557404,0.000278504,0.0002178214,0.001471556,0.02752589,0.0003055538,0.009452778,0.0414439],"study_design_scores_gemma":[0.7662007,0.2220487,0.005784065,0.00004852417,0.0003698888,0.0001692988,0.00004060786,0.000972552,0.001920138,0.0001923031,0.002224898,0.00002834134],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9744111,0.002658766,0.0008051221,0.001453812,0.0003476801,0.008203888,0.00627481,0.0003348236,0.005509945],"genre_scores_gemma":[0.968074,0.001597393,0.002669659,0.002928065,0.0003107447,0.006803985,0.01130089,0.00008478944,0.006230465],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009051218,"threshold_uncertainty_score":0.03027928,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05757121702951448,"score_gpt":0.4162801374752172,"score_spread":0.3587089204457027,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}